The George-Huntington-Institute (GHI) located in Münster, Germany is devoted to clinical care and preclinical and clinical research in Huntington’s disease (HD). GHI entertains one of the largest HD out-patient clinics for symptomatic and premanifest gene carriers, persons at-risk and caregivers around the world. GHI offers participation in ENROLL-HD, HD-Clarity and multiple clinical trials aimed at improving therapeutic options for HD.
Involved in the feasibility study as a clinical site representing the HD part of the study. Takes part in:
– Providing clinical insights to the selection technologies
– Design of the COS.
– Integrate views and opinions of patients
– Lead and coordinate the activities of the HD partners in the preparation and conduct of the COS
Target recruitment:
• Huntington’s disease – 35
• Healthy controls – 35
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.